Charles River Laboratories International (CRL) Common Equity (2009 - 2026)

Charles River Laboratories International has reported Common Equity for 18 years, with the latest figure at $2.8 billion in Q2 2026.

• On a quarterly basis, Common Equity fell 15.29% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 15.29% decrease from a year earlier, with the FY2025 full-year figure at $3.2 billion, down 8.57% from the prior year.
• Common Equity was $2.8 billion for Q2 2026 at Charles River Laboratories International, down from $2.9 billion in the prior quarter.
• The five-year high for Common Equity was $3.8 billion in Q3 2024, with the low at $2.6 billion in Q1 2022.
• Average Common Equity over 5 years is $3.2 billion, with a median of $3.2 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Common Equity advanced 25.75% in 2023, then declined 15.29% in 2026.
• Over 5 years, Common Equity stood at $3.0 billion in 2022, then grew by 20.84% to $3.6 billion in 2023, then retreated by 3.76% to $3.5 billion in 2024, then dropped by 8.57% to $3.2 billion in 2025, then declined by 10.22% to $2.8 billion in 2026.
• The last three Common Equity figures came in at $2.8 billion (Q2 2026), $2.9 billion (Q1 2026), and $3.2 billion (Q4 2025), per Business Quant data.